Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cogentus Pharmaceuticals has enrolled the first patient in Europe in the company's pivotal Phase III study of its novel combination medicine CGT-2168. The patient entered the Cogent-1 study at the Zadebie cardiology clinic in Skierniewice, Poland.
Subscribe to our email newsletter
The study, which began in North America in January, 2008 is evaluating the antiplatelet medicine CGT-2168, a combination of clopidogrel (currently marketed by Bristol-Myers Squibb and Sanofi-Aventis as Plavix) and a gastroprotectant (omeprazole) in a single pill.
Developed by Cogentus, CGT-2168 is designed to provide cardiovascular benefits while reducing potentially serious gastrointestinal side effects commonly associated with dual antiplatelet therapy.
Mark Goldsmith, Cogentus chairman and CEO, said: “Cogent has been very well received by the medical community in North America, with strong enrollment. Now we will begin to gather important data from investigators in Europe and broaden the patient base of the study.”